Avance Clinical Acquires U.S.-Based LumaBridge

Summit Partners Makes Majority Growth Investment in LumaBridge

August 23, 2022

Healthcare Services

Summit Partners has made a majority growth equity investment in LumaBridge, an oncology-focused clinical research organization (CRO) headquartered in San Antonio, Texas. The capital will support LumaBridge’s expansion of clinical trial capabilities and enable the company to serve a larger number of emerging biopharma sponsors developing immuno-oncology therapies.

Avance Clinical Acquires C3 Research Associates to Expand into North America

September 6, 2022

Healthcare Services

Avance Clinical, a PE-backed Australian CRO, has acquired North American CRO partner C3 Research Associates to expand its later‑phase clinical trial capabilities and establish a US presence. Backed by private equity firm The Riverside Company, Avance will integrate C3 into its GlobalReady model and invest in growing its North American team to support biotechs transitioning from early‑phase studies in Australia/New Zealand to later phases in the US.

The Riverside Company Invests in Avance Clinical

November 9, 2021

Healthcare Services

The Riverside Company has invested in Avance Clinical, a leading Australian contract research organisation (CRO), to support the company's regional and international expansion. The investment will help Avance accelerate its clinical trials business — including vaccine and gene-technology studies — with a particular focus on growth in North America and Asia.

Navitus Health Solutions Acquires EpiphanyRx; Lumicera Purchases Quality Drug Clinical Care

July 19, 2021

Healthcare Services

Navitus Health Solutions has acquired EpiphanyRx to broaden its PBM capabilities and mid-market employer reach. Its specialty pharmacy arm, Lumicera Health Services, also acquired Quality Drug Clinical Care in Irvine, California to expand Lumicera's specialty pharmacy footprint and HIV clinical services in the western United States.

Bruker Corporation Acquires Neurescence Inc.

November 12, 2022

Medical Devices

Bruker Corporation has signed a definitive agreement to acquire 100% of Neurescence Inc., a Toronto-based developer of ultralight fiber‑bundle Multiscopes (Chromatone) for multi-region optical functional neuroimaging. The acquisition strengthens Bruker's preclinical neuroscience imaging capabilities and complements its existing Ultima multiphoton solutions and recently acquired Inscopix products; financial terms were not disclosed.

Mural Acquires LUMA Institute

March 28, 2022

Education

Mural, the San Francisco–based provider of digital workspaces for visual collaboration, acquired LUMA Institute, a leading provider of design-thinking training, certifications, and digital learning resources. The acquisition expands Mural’s collaboration capabilities by integrating LUMA’s learning experiences and methods to accelerate adoption of collaboration design at enterprise scale.